Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)
Status:
Withdrawn
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
This study is a phase I, open label, randomized study to assess pharmacokinetics,
biodistribution and radiation dosimetry of lutetium (177Lu) lilotomab satetraxetan
(Betalutin®) radioimmunotherapy in patients with relapsed non-Hodgkin lymphoma. The study
will also investigate the safety, toxicity and efficacy of Betalutin and pre-dosing.